Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Comment by wrongturnon Apr 04, 2009 2:27am
752 Views
Post# 15896547

RE: A comment about Novartis

RE: A comment about NovartisSo the eye ball indication hits the market later this year with Lux?

Psoarisis, as it is de-risked and hopefully approved by the FDA et al next year, Novartis comes in as a partner?  And if not approved by the FDA.......then no partner?

So the vultures wait to see how ISA does as a company.  If it is able to carry its own weight until later next year and hopefully bring psoarisis to market, at that point a partner comes in, congratulates ISA for surviving, and proposes a deal?

Doesn't Novartis own 30% of Roche or vice versa?  So as long as 1 can't cash in, the other can smash the crap out of a company and the sister cashes in?  Working with large pharma, damned if you do and damned if you don't.

I wonder if Novartis will try to hold back psoarisis until 2013 with tx?  But why would they if voclo is already on the market with uveitis?

I would appreciate anybody's comments on when the patent clock(s) start to tick?

Bullboard Posts